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ABSTRACT
Background. Patients with palpable melanoma groin
metastases have a poor prognosis. There is debate whether
a combined superficial and deep groin dissection (CGD) is
necessary or if superficial groin dissection (SGD) alone is
sufficient.
Aim. The aim of this study was to analyze risk factors for
deep pelvic nodal involvement in a retrospective, multi-
center cohort of palpable groin melanoma metastases. This
could aid in the development of an algorithm for selective
surgery in the future.
Methods. This study related to 209 therapeutic CGDs
from four tertiary centers in The Netherlands (1992–2013),
selected based on complete preoperative imaging and
pathology reports. Analyzed risk factors included baseline
and primary tumor characteristics, total and positive
number of inguinal nodes, inguinal lymph node ratio
(LNR) and positive deep pelvic nodes on imaging
(computed tomography [CT] ± positron emission tomog-
raphy [PET], or PET - low-dose CT).
Results. Median age was 57 years, 54 % of patients were
female, and median follow-up was 21 months (interquartile
range [IQR] 11–46 months). Median Breslow thickness
was 2.10 mm (IQR 1.40–3.40 mm), and 26 % of all pri-
mary melanomas were ulcerated. Positive deep pelvic
nodes occurred in 35 % of CGDs. Significantly fewer in-
guinal nodes were positive in case of negative deep pelvic
nodes (median 1 [IQR 1–2] vs. 3 [IQR 1–4] for positive
deep pelvic nodes; p\ 0.001), and LNR was significantly
lower for negative versus positive deep pelvic nodes [me-
dian 0.15 (IQR 0.10–0.25) vs. 0.33 (IQR 0.14–0.54);
p\ 0.001]. A combination of negative imaging, low LNR,
low number of positive inguinal nodes, and no extracap-
sular extension (ECE) could accurately predict the absence
of pelvic nodal involvement in 84 % of patients.
Conclusions. Patients with negative imaging, few positive
inguinal nodes, no ECE, and low LNR have a low risk of
positive deep pelvic nodes and may safely undergo SGD
alone.
Patients with clinically palpable nodal metastases of
cutaneous melanoma in the groin have a poor prognosis.
Balch et al. reported a 5 year overall survival (OS) rate of
59 % for stage IIIB melanoma in the 2009 American Joint
 The Author(s) 2015. This article is published with open access
at Springerlink.com
First Received: 24 February 2015;
Published Online: 27 May 2015
C. M. C. Oude Ophuis, MD
e-mail: c.oudeophuis@erasmusmc.nl
Ann Surg Oncol (2015) 22:S1172–S1180
DOI 10.1245/s10434-015-4602-4
Committee on Cancer (AJCC) melanoma staging system
analysis.1 Reported 5 year OS rates for the subgroup of
patients with palpable groin metastases ranged from 52 %
for superficial involvement to 12 % for deep
involvement.2–7
Standard of care for these patients consists of
therapeutic lymph node dissection (TLND),2,8–10 and there
is ongoing debate as to whether this should consist of either
a combined superficial and deep groin dissection (CGD) or
whether a superficial groin dissection (SGD) would suffice.
Several cohort studies indicate no difference in survival
between these two procedures, and patients may benefit
from SGD alone if no positive deep pelvic nodes are pre-
sent on preoperative imaging.2,8,10–12
Since the estimated prevalence of positive deep pelvic
nodes in patients with palpable inguinal lymph nodes is
30 %, the majority of patients undergoing CGD may not
benefit from deep groin dissection (DGD).6,12 As CGD is a
more extensive procedure than SGD, the risk of morbidity
is potentially higher.6 A clear need exists to select those
patients who can be safely spared a DGD in the absence of
deep pelvic nodal involvement.10,11,13–15
Preoperative imaging techniques such as computed to-
mography (CT) and positron emission tomography (PET)
form a valuable adjunct to staging. Up to 27 % of patients
presenting with palpable lymph node metastases have
synchronous distant metastases at preoperative PET/CT,
which changes the indication for surgery into palliative
resection and/or systemic therapy.16 Additionally, imaging
provides assessment of suspicious deep pelvic nodes prior
to surgery. High positive (PPV) and negative predictive
value (NPV) have been achieved by Allan et al. (100 and
86 %, respectively).3 Other series reported PPVs and NPVs
of 40–60 %, which is too low to confirm or reject the
presence of positive deep pelvic nodes based on preop-
erative imaging alone.2,17,18 Once suspicious deep pelvic
nodes are detected on preoperative imaging, one cannot
ignore their presence and CGD is highly recommended.
The absence of suspicious deep pelvic nodes on imaging
does not rule out deep pelvic nodal involvement. Once
imaging has been performed, the focus should be on
identification of further risk factors for positive deep pelvic
nodes.2,7,11, 15,17–21
PATIENTS AND METHODS
Patients
This retrospective, multicenter cohort study described
209 therapeutic CGDs performed at four tertiary melanoma
centers in The Netherlands between 1992 and 2013. Patient
selection was based on the presence of a palpable nodal
metastasis to the groin, complete pathology reports of the
performed CGD (i.e. clearly describing the dissected
lymph nodes as inguinal or iliac, including obturator area),
and preoperative imaging (CT, PET, or PET/CT). Patients
without imaging, with prior lymph node dissections in the
groin area, or with isolated limb perfusion or positive
sentinel node(s) as an indication for CGD were excluded.
Analyzed preoperative imaging modalities were CT scan,
PET, and combined PET with low-dose CT (PET/CT).
All patient characteristics were obtained from medical
records and collected in a database for the current study,
according to local Institutional Review Committee guide-
lines and national legislation.
Surgical Procedure
CGD was performed either via two separate transverse
incisions or via an inguinal ellipse-shaped incision ex-
tending cranially according to local preferences per center,
as described in detail elsewhere.6,22
Pathology
CGD pathology reports were considered adequate when
a clear description was given of the total number of in-
guinal nodes as well as the number of tumor-positive
inguinal nodes, and a similar description was given of the
number of dissected deep pelvic nodes (iliac nodes and
obturator nodes) and the number of tumor-positive deep
pelvic nodes.
Statistics/Data Analysis
Patients were divided into two categories based on deep
pelvic nodal status—positive or negative. Univariable v2
tests were performed to test for significant differences in
prevalence of sex, primary tumor located on the trunk,
primary tumor stage (T1–T4), ulceration, and inguinal
extracapsular extension (ECE). Nonparametric tests were
performed to test for differences in age, median Breslow
thickness, total number of inguinal nodes and number of
positive inguinal nodes, total number of excised nodes and
number of positive nodes, total number of deep pelvic
nodes, number of positive deep pelvic nodes, and LNR.
Sensitivity, specificity, PPV, NPV, and accuracy were
calculated for all imaging modalities using the number of
true positives (TP), false positives (FP), true negatives
(TN), and false negatives (FN).
Differences in baseline characteristics were tested using
univariable logistic regression analysis, multivariable
models were calculated using variables significant at uni-
variable analysis, and binary logistic multivariable
regression analyses were performed to test for independent
predictors of deep pelvic nodal involvement.
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Ridge regression analysis was performed to exclude the
influence of multicollinearity in a prediction model based
on independent predictive variables. An area under the
receiver operating characteristic curve (AUC) was calcu-
lated for the model. The AUC indicates the probability that
patients with observed positive deep pelvic nodes had a
higher predicted probability than patients with observed
negative deep pelvic nodes, providing information about
the predictive value of the model.
All statistical analyses, with the exception of Ridge re-
gression, were performed using SPSS version 21.0
(released 2012; IBM Corporation, Armonk, NY, USA).
Ridge regression was performed using RStudio (RStudio
Inc., Boston, MA, USA). An a\ 0.05 was considered
significant.
RESULTS
Patients
Table 1 provides an overview of baseline characteris-
tics. The majority of patients (n = 201, 96 %) had palpable
stage IIIB disease, and eight patients (4 %) had stage IV
disease. Median Breslow thickness was 2.10 mm (in-
terquartile range [IQR] 1.4–3.4 mm), 12 patients had a
history of negative sentinel node, and median follow-up
was 21 months (IQR 11–46 months).
Imaging and Pathology
Four patients underwent both CT and PET/CT; they
were scored as PET/CT since the additional information
obtained from PET/CT was used for the final determination
of clinical node status. Predictive accuracy per imaging
modality is shown in Table 2. The different imaging
modalities were used equally between the two groups (i.e.
positive or negative deep pelvic nodes).
Logistic Regression Analysis
Variables significantly different on univariable analysis
(Table 1) were included in multivariable binary logistic
regression analyses. LNR and number of positive inguinal
lymph nodes were assessed in separate models due to
evident multicollinearity. The remaining significant inde-
pendent predictors were suspicious deep pelvic nodes on
imaging (odds ratio [OR] 9.64, 95 % CI 4.35–21.3,
p\ 0.001), increasing LNR (OR 34.2, 95 % CI 5.47–214,
p\ 0.001), the presence of ECE (OR 2.13, 95 % CI 1.01–
4.48, p = 0.046) and, in a separate multivariable model
without LNR, increasing number of positive inguinal
lymph nodes (OR 1.27, 95 % CI 1.06–1.53, p = 0.010).
Subgroup Analysis Negative Imaging
Suspicious deep pelvic nodes on imaging were highly
predictive for positive deep pelvic nodes. A subgroup of
155 patients without suspicious deep pelvic nodes on
imaging was selected for further analysis of additional risk
factors for positive deep pelvic nodes. Thirty-five of these
patients (23 %) had positive deep pelvic nodes at
histopathological examination with hematoxylin and eosin
(H&E) staining, i.e. imaging was FN. Univariable analysis
results are displayed in Table 3. Multivariable analysis was
performed, including all significant variables assumed to be
predictive for deep pelvic nodal status: number of positive
inguinal nodes, LNR, and ECE status. Evident multi-
collinearity was observed.
To overcome this problem, a predictive Ridge logistic
regression analysis was performed. Only LNR remained as
a significant independent predictor for positive deep pelvic
nodes (p = 0.014). The number of positive inguinal lymph
nodes and ECE were chosen to remain in the model as
contributing covariates as these were thought to be of
substantial additional clinical relevance. A receiver oper-
ating characteristic (ROC) curve of the predicted
probabilities for positive deep pelvic nodes was created,
displaying a fair AUC of 0.72 (AUC values ranged be-
tween 0 and 1, where high scores are indicative of high
accuracy) (Fig. 1). The optimum cut-off value for the
predicted probability of the model (i.e. the probability at
which the model outcome correctly identifies an observed
positive patient as positive) was chosen based on high
specificity in order to minimize FN outcomes. Corre-
sponding probability cut-off value and sensitivity were
deduced from the ROC curve. For a specificity of 90 %, the
cut-off value for a positive test outcome was a probability
for positive deep pelvic nodes of 32 % or more. Sensitivity
was 43 %, PPV 50 %, NPV 84 %, and overall accuracy of
this model was 77 %.
DISCUSSION
In this CGD cohort, 35 % of all patients had deep pelvic
nodal involvement, which is in line with the lit-
erature.10,11,13–15 This study analyses risk factors to
identify deep pelvic nodal involvement, with imaging be-
ing a strong predictor. Our prediction model might lower
the rate of CGD without positive pelvic nodes, and mini-
mizes the number of FN outcomes after imaging.
Imaging
The imaging modalities used in this study are fair in
correctly predicting positive deep pelvic nodes; however, a
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TABLE 1 Baseline characteristics
Characteristic Total [n = 209 (100 %)] Negative pelvic
nodes [n = 135 (65 %)]
Positive pelvic
nodes [n = 74 (35 %)]
p value
Sex
Female 114 (54) 76 (56) 38 (51) 0.49
Male 95 (46) 59 (44) 36 (49)
Age [years; median (IQR)] 57 (45–65) 55 (46–65) 59 (44–65) 0.63
Center
1 60 (29) 42 (31) 18 (24) 0.21
2 57 (27) 38 (28) 19 (26)
3 24 (12) 11 (8) 13 (18)
4 68 (32) 44 (33) 24 (32)
Tumor stage
T1 22 (11) 9 (7) 13 (18) 0.16
T2 57 (27) 36 (27) 21 (28)
T3 60 (29) 39 (29) 21 (28)
T4 30 (14) 22 (16) 8 (11)
Unknown primary 10 (5) 8 (6) 2 (3)
Missing 30 (14) 21 (15) 9 (12)
Ulceration
Absent 125 (60) 74 (55) 51 (69) 0.16
Present 54 (26) 38 (28) 16 (22)
Missing 30 (14) 23 (17) 7 (9)
Clark levela
II 1 (0.5) 0 (–) 1 (1) 0.29
III 35 (17) 22 (16) 13 (17)
IV 84 (40) 54 (40) 30 (41)
V 13 (6) 11 (8) 2 (3)
Missing 76 (36.5) 48 (36) 28 (38)
Location
Leg 166 (80) 106 (79) 60 (81) 0.62
Trunk 28 (13) 17 (13) 11 (15)
Unknown primary 10 (5) 8 (6) 2 (3)
Missing 5 (2) 4 (3) 1 (1)
Histology
SSM 67 (32) 44 (32) 23 (31) 0.24
NM 37 (18) 28 (21) 9 (12)
Other 15 (7) 9 (7) 6 (8)
Unknown primary 10 (5) 8 (6) 2 (3)
Missing 80 (38) 46 (34) 34 (46)
No. of nodes [median (IQR)]
Inguinal 10 (7–13) 10 (7–13) 9 (7–12) 0.54
Deep 6 (4–10) 6 (4–9) 8 (5–11) 0.039b
Total 17 (13–22) 17 (13–21) 17 (14–22) 0.39
No. of positive nodes [median (IQR)]
Inguinal 2 (1–3) 1 (1–2) 3 (1–4) \0.001b
Deep 0 (0–1) 0 (0) 2 (1–3) \0.001b
Total 2 (1–4) 1 (1–2) 5 (3–7) \0.001b
LNR [median (IQR)] 0.20 (0.11–0.33) 0.15 (0.10–0.25) 0.33 (0.14–0.54) \0.001b
Inguinal ECE
No 134 (64) 94 (70) 40 (54) 0.025b
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considerable number of patients have FP imaging (20–
32 %), and we can only speculate on the possible causes of
FP imaging. This might be partially explained by a small
group of patients undergoing diagnostic excision biopsy of
the palpable lymph node prior to imaging, which might
cause lymph node enlargement in the pelvic area. Another
cause may be the inevitable interobserver variability in
radiology. Improvement of imaging techniques over time
may have altered the number of FP lymph nodes detected
during the present study period.
NPVs of the preoperative imaging techniques performed
in the current study range between 70 and 83 %, leaving a
substantial proportion of 23 % (17–30 %) of patients to be
falsely diagnosed with negative deep pelvic nodes. Several
studies have reported on the NPV of CT, and although high
NPVs have been described by Allan et al. and Van der
Ploeg et al. overall reported values ranged consider-
ably.2,3,6,17,18 Ongoing development of the newest imaging
techniques, such as the use of a melanoma-specific PET
tracer ([18F]ICF01006), may enhance the accuracy of
imaging and subsequently decrease the FN rate.23
Predictive Factors
Predictive factors for deep pelvic nodal involvement
found in the current study are inguinal nodal status as
defined by the number of positive inguinal nodes and
LNR, inguinal ECE, and suspicious deep pelvic nodes on
preoperative imaging, which is concordant with the lit-
erature.2,7,11,15,17–21 These risk factors may be applied to
select patients for SGD, in addition to imaging without
suspicious deep pelvic nodes. A hypothetical two-stage
approach would be when preoperative imaging is nega-
tive, patients first solely undergo an SGD. The pathology
results can then be used to determine the risk of occult
positive deep pelvic nodes, and a decision can be made on
whether to perform an additional DGD or not. The fact
that patients must undergo two separate operations is a
drawback, but this way a DGD can be spared in 126 of all
patients (60 %).
Patient Selection
Standard CGD for palpable stage III melanoma shows
that 135 of 209 deep pelvic groin dissections (65 %) have
been performed in the absence of pelvic nodal metastases.
Use of preoperative imaging alone for selection between
CGD and SGD would reduce the number of CGDs from
209 to 54. The remaining 155 patients would undergo SGD
alone. Thirty-five of these 155 patients undergoing SGD
alone were FN (FN rate 23 %) and would possibly be
undertreated (i.e. undergoing no DGD).
TABLE 1 continued
Characteristic Total [n = 209 (100 %)] Negative pelvic
nodes [n = 135 (65 %)]
Positive pelvic
nodes [n = 74 (35 %)]
p value
Yes 75 (36) 41 (30) 34 (46)
Data are expressed as n (%) unless otherwise specified
IQR interquartile range, T1 Breslow\ 1.00 mm, T2 Breslow 1.01–2.00 mm, T3 Breslow 2.01–4.00 mm, T4 Breslow[ 4.00 mm, LNR inguinal
lymph node ratio, ECE extracapsular extension
a Clark levels II and III were combined for the v2 test
b Significant, p\ 0.05, calculated using v2 and non-parametric tests
TABLE 2 Identification of positive deep pelvic lymph nodes using preoperative imaging techniques (n = 209)
CT (%) [n = 67] CT and/or PET (%) [n = 57]a PET/CT (%) [n = 85]b
Sensitivity 57 36 61
Specificity 93 94 83
PPV 80 73 68
NPV 83 70 79
Accuracy 82 70 75
CT computed tomography, PET position emission tomography, PET/CT combined PET and low-dose CT, PPV positive predictive value, NPV
negative predictive value
a Thirteen patients underwent PET alone
b Four patients also underwent separate CT
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TABLE 3 Baseline characteristics for patients with negative preoperative imaging
Characteristic Total (n = 155) Pelvic nodes- (n = 120) Pelvic nodes? (n = 35) p value
Sex
Female 83 (54) 67 (56) 16 (46)
Male 72 (46) 53 (44) 19 (54) 0.29
Age [years; median (IQR)] 56 (45–64) 55 (46–65) 57 (44–64) 0.99
Center
1 44 (28) 38 (32) 6 (17)
2 48 (31) 35 (29) 13 (37)
3 18 (12) 10 (8) 8 (23)
4 45 (29) 37 (31) 8 (23) 0.17
Breslow [median (IQR)] 2.10 (1.40–3.25) 2.20 (1.45–3.55) 1.90 (1.15–2.80) 0.11
Tumor stage
T1 14 (9) 8 (7) 6 (17)
T2 45 (29) 33 (28) 12 (34)
T3 44 (28) 37 (31) 7 (20)
T4 23 (15) 19 (16) 4 (11)
Unknown primary 9 (6) 7 (6) 2 (6)
Missing 20 (13) 16 (13) 4 (11) 0.38
Ulceration
Absent 90 (58) 67 (56) 23 (66)
Present 44 (28) 36 (31) 8 (23)
Missing 21 (14) 17 (13) 4 (11) 0.34
Clark levela
II 1 (0.6) 0 (–) 1 (3)
III 25 (16) 20 (17) 5 (14)
IV 65 (42) 49 (41) 16 (46)
V 11 (7) 11 (9) 0 (–)
Missing 53 (34) 40 (33) 13 (37) 0.070
Location
Leg 118 (76) 93 (78) 25 (71)
Trunk 23 (15) 16 (13) 7 (20)
Unknown primary 9 (6) 7 (6) 2 (6)
Missing 5 (3) 4 (3) 1 (3) 0.81
Histology
SSM 52 (34) 40 (33) 5 (14)
NM 31 (20) 26 (22) 12 (34)
Other 10 (6) 8 (7) 2 (6)
Unknown primary 9 (6) 7 (6) 2 (6)
Missing 53 (34) 39 (32) 14 (40) 0.86
No. of nodes [median (IQR)]
Total 17 (13–21) 17 (13–21) 17 (14–22) 0.42
Inguinal 10 (8–12) 10 (8–13) 9 (8–12) 0.69
Deep 6 (4–9) 6 (4–9) 7 (4–11) 0.15
No. of positive nodes [median (IQR)]
Total 2 (1–4) 1 (1–2) 5 (3–6) \0.001b
Inguinal 1 (1–3) 1 (1–2) 3 (1–4) \0.001b
Deep 0 (0) 0 (0) 2 (1–2) \0.001b
LNR [median (IQR)] 0.17 (0.11–0.31) 0.21 (0.10–0.25) 0.33 (0.13–0.50) 0.001b
ECE inguinal
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Better patient selection is necessary in the negative
imaging group as a potential decrease in the number of FNs
will make patient selection safer. This formed the rationale
for the prediction model, which is based on 153 patients
(155—2 patients with missing data) with negative imaging.
Using this model, 124 of 153 patients would undergo SGD
alone, and FN rates would be reduced to 20 of 124 patients
(FN rate 16 %).
Concluding, this model forms an adjunct to the use of
preoperative imaging as a selection tool for SGD or CGD,
both drastically minimizing the number of patients without
affected pelvic nodes undergoing a DGD, and controlling
the number of patients with affected pelvic nodes poten-
tially being undertreated by not undergoing a DGD.
The 16 % FN rate of this model is still considerable.
Although surgery forms the cornerstone of melanoma
treatment, one may question the role of DGD in the current
era of upcoming effective systemic treatments. On one hand,
the majority of patients undergoing standard CGD for pal-
pable groin metastases have negative deep pelvic nodes,
while on the other hand there is evidence to assume that
positive deep pelvic nodes may merely be a biomarker for
stage IV disease as survival rates depend on deep pelvic
nodal status rather than extent of surgery.6,8,11,12,15 Khos-
rotehrani et al. presented a nomogram for the prediction of
prognosis in stage III B/C melanoma patients, using
pathology results and age.24 Application of this nomogram
could further aid in selecting patients for SGD alone.
Another preoperative aid in addition to the presented model
could be use of the biomarker S-100B. As Kruijff et al. have
shown, high serum levels of S-100B are associated with a
significantly lower disease-free survival and a trend towards
worse melanoma-specific survival (MSS), indicating its
potential as a biomarker for clinically occult stage IV dis-
ease.25,26 Patients with a low risk of deep pelvic nodal
involvement and low S-100B could then undergo SGD
alone, with regular control visits to detect early signs of deep
pelvic nodal involvement (suspicious nodes on imaging/
elevated S-100B). Bearing this in mind, the 16 % FN rate of
the presented prediction model may be allowable.
Limitations
This study was retrospective and was spread over a long
timeframe. This entails inevitable alterations and im-
provement of imaging techniques and clinical practice over
time, affecting our results. The prediction model designed
for the current study has not been validated internally due
to a small sample of patients with positive deep pelvic
nodes. It has to be pointed out that this model in its current
state is not suited for clinical use as there is still much to be
gained from further development and testing. A prospec-
tive, multicenter registration study is planned, enabling
adequate data collection on all patients undergoing CGD
for palpable groin metastases within a relatively small
timeframe. Cross-validation of the presented prediction
model will be performed and its role in future clinical
practice will be further defined. With the proposed
prospective study, accuracy of imaging techniques can be
determined more adequately.
Regarding the possible additional morbidity of a DGD,
although to date no prospective randomized controlled
trial (RCT) has been performed to address this, evidence
exists that the additional morbidity of DGD in a CGD
might be more limited than has been described in the
past.6,22 The recently opened Australia and New Zealand
Melanoma Trials Group 01.12 Evaluation of Groin
Lymphadenectomy Extent For Metastatic Melanoma
(EAGLE FM) trial (clinicaltrials.gov identifier
NCT02166788) will hopefully provide an answer to this
question. This multicenter RCT compares SGD and CGD
for melanoma patients with groin metastases and no sus-
picious PET/CT scan.
As operating time is generally longer in a CGD, there is
a potentially higher risk of surgical site infections. In the
large, retrospective series of Glarner et al. the number of
surgical site infections is indeed significantly higher for
CGDs, with an adjusted OR of 2.6.27 Once again, to gain
more insight into the actual differences in morbidity be-
tween SGD and CGD, we will have to await results from
the EAGLE FM Trial.
TABLE 3 continued
Characteristic Total (n = 155) Pelvic nodes- (n = 120) Pelvic nodes? (n = 35) p value
No 96 (62) 79 (66) 17 (49)
Yes 59 (38) 41 (34) 18 (51) 0.075
Data are expressed as n (%) unless otherwise specified
IQR interquartile range, T1 Breslow\ 1.00 mm, T2 Breslow 1.01–2.00 mm, T3 Breslow 2.01–4.00 mm, T4 Breslow[ 4.00 mm, LNR inguinal
lymph node ratio, ECE extracapsular extension
a For the v2 test, Clark II and III were combined
b Significant (p\ 0.05)
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CONCLUSIONS
High LNR, high number of positive inguinal nodes, and
inguinal ECE are risk factors for positive deep pelvic nodes
in patients with palpable groin metastases of cutaneous
melanoma. To date, accurate prediction of deep pelvic
nodal status is still suboptimal, hence reliable selection of
patients who can be spared a DGD remains difficult.
Combined use of preoperative imaging and a preliminary
prediction model based on histopathology results of the
inguinal (superficial) part of CGD could accurately predict
negative deep pelvic nodes in up to 84 % of patients,
thereby potentially identifying a group of low-risk patients
in whom the extent of surgery might safely be minimized.
The risk factors and the prediction model will be further
investigated in a prospective, multicenter registry trial for
CGDs.
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